Skip to content

Trial Summary

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib.



ACTRN/NCT /ethics:


Scientific title:

A Phase 1 dose escalation and expansion study to evaluate safety, tolerability, pharmacokinetic, pharmacodynamic, and anti-tumor activity of PF-07248144 in participants with advanced or metastatic solid tumors.

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-11-16
Anticipated End Date2025-04-18

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Phone08 8359 2565
Principal InvestigatorA/Prof Rohit Joshi
Recruitment StatusRecruiting